Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CAPOTEN | Strides Pharma Global | N-018343 DISCN | 1982-01-01 | 7 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CAPOZIDE 25/15 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
CAPOZIDE 25/25 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
CAPOZIDE 50/25 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
CAPOZIDE 50/15 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
captopril | ANDA | 2024-10-15 |
captopril and hydrochlorothiazide | ANDA | 2023-02-21 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 6 | 1 | 2 | 8 | 7 | 23 |
Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | 1 | 10 | 11 |
Heart failure | D006333 | HP_0001635 | I50 | 1 | — | 1 | 2 | 3 | 7 |
Covid-19 | D000086382 | — | — | — | 2 | 2 | 1 | 1 | 6 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 2 | 1 | 3 | 6 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | 3 | 1 | 5 |
Healthy volunteers/patients | — | — | — | 3 | — | — | 1 | — | 4 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | 1 | 1 | 3 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | 1 | 2 | 3 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | 3 | — | — | 3 |
Essential hypertension | D000075222 | — | I10 | 1 | 1 | 1 | — | 1 | 3 |
Neoplasms | D009369 | — | C80 | 2 | 2 | 1 | — | — | 3 |
Pneumonia | D011014 | EFO_0003106 | — | — | 1 | 1 | — | — | 2 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | 1 | — | 1 | 2 |
Malaria | D008288 | EFO_0001068 | B54 | — | — | 1 | — | — | 1 |
Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 1 | — | — | 1 |
Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | — | 1 | — | — | 1 |
Leukemia | D007938 | — | C95 | — | — | 1 | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Blood pressure | D001794 | EFO_0004325 | — | 1 | 1 | — | — | — | 2 |
Fibrosis | D005355 | — | — | 1 | 2 | — | — | — | 2 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | 1 | 2 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | — | 1 |
Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 1 | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | 1 | — | — | — | 1 |
Radiation injuries | D011832 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pure autonomic failure | D054970 | — | — | 2 | — | — | — | — | 2 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | — | — | — | 1 | 2 |
Shy-drager syndrome | D012791 | EFO_1001050 | — | 1 | — | — | — | — | 1 |
Multiple system atrophy | D019578 | — | — | 1 | — | — | — | — | 1 |
Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | 1 | — | — | — | — | 1 |
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | — | 1 |
Muscular dystrophies | D009136 | HP_0003560 | G71.0 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 2 | 2 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 2 | 2 |
Mitral valve insufficiency | D008944 | HP_0001653 | — | — | — | — | — | 2 | 2 |
Aneurysm | D000783 | HP_0002617 | I72.9 | — | — | — | — | 1 | 1 |
Thoracic aortic aneurysm | D017545 | EFO_0004282 | — | — | — | — | — | 1 | 1 |
Aortic aneurysm | D001014 | EFO_0001666 | I71.9 | — | — | — | — | 1 | 1 |
Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | — | 1 | 1 |
Peri-implantitis | D057873 | EFO_1001390 | — | — | — | — | — | 1 | 1 |
Heart murmurs | D006337 | HP_0030148 | R01.0 | — | — | — | — | 1 | 1 |
Drug common name | Captopril |
INN | captopril |
Description | Captopril is a L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and an antihypertensive agent. It is a pyrrolidinemonocarboxylic acid, a N-acylpyrrolidine, an alkanethiol and a L-proline derivative. |
Classification | Small molecule |
Drug class | aptamers, classical and mirror; antihypertensives (ACE inhibitors) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O |
PDB | — |
CAS-ID | 62571-86-2 |
RxCUI | — |
ChEMBL ID | CHEMBL1560 |
ChEBI ID | 3380 |
PubChem CID | 44093 |
DrugBank | DB01197 |
UNII ID | 9G64RSX1XD (ChemIDplus, GSRS) |